ArticleInternational journal of nanomedicine2019
Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.Cancer metastasis reviews · 2023Review
- Targeted Drug Delivery for Chronic Lymphocytic Leukemia.Pharmaceutical research · 2022Review
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
- Nanozyme for tumor therapy: Surface modification matters.Exploration (Beijing, China) · 2021Review
- Applications of Nanoparticle-Antibody Conjugates in Immunoassays and Tumor Imaging.The AAPS journal · 2021Review
- A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection.BMC infectious diseases · 2021Article
- Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.Biomaterials · 2020Article
- Rotating magnetic field delays human umbilical vein endothelial cell aging and prolongs the lifespan ofAging · 2019Article
- Emerging Advances in Nanomedicine for Targeted Cancer Photoimmunotherapy and Photo-Immunometabolic Therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands of lives. However, many people cannot benefit from rituximab treatment because of drug resistance or side effects.
methodsIn this study, a 13-nm rituximab-conjugated magnetic nanoparticle was developed as a therapeutic nanoprobe targeting CD20 overexpressing malignant lymphoma cells to enhance the treatment effects of rituximab. The magnetic cores (2,3-dimercaptosuccinicacid modified Fe
resultsCell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe
conclusionThese results indicate that Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.